POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-196648 | Health Care
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Postmenopausal Vaginal Atrophy Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET
7.1 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA POSTMENOPAUSAL VAGINAL ATROPHY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Actavis Generics (United States)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bionovo (Saudi Arabia)
16.3 Endoceutics, Inc. (Canada)
16.4 Upsher-Smith Laboratories, LLC (United States)
16.5 Novo Nordisk A
16.6 S (Denmark)
16.7 Pfizer Inc. (United States)
16.8 Teva Pharmaceutical Industries Ltd. (Isreal)
16.9 Therapeutics MD, Inc. (United States)
16.10 Shionogi & Company, Limited (Japan)
16.11 Allergan plc (Ireland)
16.12 Ligand Pharmaceuticals (United States)
16.13 Bayer HealthCare LLC (United States)
16.14 Pantarhei Bioscience (Netherland)
16.15 VYNE Therapeutics Inc. (United States)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Drug FormVaginal gel
Creams
Tablet
Others
By Drug
Estrogen based drugs (Premarin Vagifem Estrace Estring and Femring)
Non-estrogen based drugs (BZA/CE Osphena and Vaginorm)
Others
By Route of Administration
Oral
Intravaginal
Others
By End User
Hospitals
Specialty Clinics
Others
Companies
Actavis Generics (United States)
Bionovo (Saudi Arabia)
Endoceutics, Inc. (Canada)
Upsher-Smith Laboratories, LLC (United States)
Novo Nordisk A
S (Denmark)
Pfizer Inc. (United States)
Teva Pharmaceutical Industries Ltd. (Isreal)
Therapeutics MD, Inc. (United States)
Shionogi & Company, Limited (Japan)
Allergan plc (Ireland)
Ligand Pharmaceuticals (United States)
Bayer HealthCare LLC (United States)
Pantarhei Bioscience (Netherland)
VYNE Therapeutics Inc. (United States)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.